(Q42363547)

28 October 2017

Clarithromycin significantly increases linezolid serum concentrations (English)

1 reference

28 October 2017

1 reference

1 reference

2

Richard van Altena

0 references

Tjip S van der Werf

object named as

Tjip S van der Werf

4

1 reference

ORCID Public Data File 2021

author name string

Mathieu S Bolhuis

1

1 reference

28 October 2017

Richard van Altena

2

1 reference

28 October 2017

Donald R A Uges

3

1 reference

28 October 2017

Jos G W Kosterink

5

1 reference

28 October 2017

Jan-Willem C Alffenaar

6

1 reference

28 October 2017

language of work or name

English

0 references

publication date

13 September 2010

1 reference

Antimicrobial Agents and Chemotherapy

28 October 2017

1 reference

28 October 2017

54

1 reference

28 October 2017

12

1 reference

28 October 2017

5418-5419

1 reference

Limited sampling strategies for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis

28 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2981294

Linezolid: a review of safety and tolerability

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2981294

Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2981294

Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB)--a report of ten cases

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2981294

In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2981294

Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis.

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2981294

Role of p-glycoprotein inhibition for drug interactions: evidence from in vitro and pharmacoepidemiological studies

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2981294

Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2981294

In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2981294

17 August 2018

Identifiers

DOI

10.1128/AAC.00757-10

1 reference

28 October 2017

1 reference

28 October 2017

1 reference